Business
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company’s Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U8Q3xNkSuAPosRUnHeWZmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company’s Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed.","length":533,"tagName":"p"},{"type":"text","content":"“Nadav is a fantastic addition to the Board,” said Company CEO and Chairman of the Board Mr. Uzi Sofer. “He has spent many years in a position much like ours, at the helm of a public company innovating a therapeutic modality for patients, and I am sure that he will prove to be an immensely valuable asset to the Company in executing our strategy as we continue to move closer towards commercialization. We look forward to benefitting from his insights and experience in the coming years.”","length":489,"tagName":"p"},{"type":"text","content":"“I am delighted to join Alpha Tau’s Board of Directors,” commented Mr. Kidron. “The Company is making incredible strides towards revolutionizing the field of oncology therapeutics, and I look forward to contributing to that critical mission.”","length":242,"tagName":"p"},{"type":"text","content":"Mr. Kidron was appointed President, Chief Executive Officer and director of Oramed in March 2006, and Chairman of the board effective as of June 30, 2022. He is also Chairman of the board of MDG Real Estate Global, Ltd., director of Israel Advanced Technology Industries Organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Tra...